Are corticosteroids (steroids) helpful in relieving malignant partial bowel obstruction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Steroids are not recommended as a treatment option for malignant partial bowel obstruction, as the evidence does not support their efficacy in improving symptoms or quality of life. The most recent and highest quality study, 1, found that corticosteroids were not effective in managing malignant bowel obstruction, and instead recommended other treatments such as surgery, stenting, decompression percutaneous gastrostomy tube, nasogastric tube, or octreotide.

Treatment Options

Other treatment options for malignant partial bowel obstruction include:

  • Surgery: may be considered in patients with a reversible cause, good performance status, and lack of complicating factors
  • Stenting: a minimally invasive procedure that can help relieve obstruction
  • Decompression percutaneous gastrostomy tube: can help relieve symptoms of nausea and vomiting
  • Nasogastric tube: can help relieve symptoms of nausea and vomiting, but is usually uncomfortable and increases the risk of aspiration
  • Octreotide: a medication that can help reduce symptoms of nausea and vomiting

Medication Management

Medications such as opioids, antiemetics, and anticholinergics may be used to manage symptoms of malignant partial bowel obstruction, but corticosteroids are not recommended due to lack of evidence supporting their efficacy. Octreotide, on the other hand, has been shown to be effective in reducing symptoms of nausea and vomiting, and can be considered as part of a comprehensive treatment plan 1.

Quality of Life

The primary goal of treatment for malignant partial bowel obstruction should be to improve quality of life, rather than just relieving symptoms. Treatment plans should be individualized and take into account the patient's overall health, performance status, and preferences. By prioritizing quality of life and using evidence-based treatments, healthcare providers can help patients with malignant partial bowel obstruction manage their symptoms and improve their overall well-being.

From the Research

Steroids in Malignant Partial Bowel Obstruction

  • The use of steroids, specifically dexamethasone, in combination with other medications such as octreotide and metoclopramide, has been studied in the management of malignant bowel obstruction (MBO) 2, 3, 4.
  • These studies suggest that the combination of dexamethasone, octreotide, and metoclopramide may lead to relief of obstruction and improvement in symptoms associated with the obstruction, including nausea, pain, and resumption of oral intake 2, 3.
  • However, one study found no statistically significant difference in rates of de-obstruction between patients who received triple therapy and those who received no drug therapy, although there was a non-significant trend toward improved de-obstruction in the triple therapy group 4.
  • The MASCC guideline update recommends the use of octreotide in non-operable MBO, and suggests that olanzapine or metoclopramide may be effective in reducing nausea and vomiting secondary to partial bowel obstructions, but notes that additional studies are needed to clarify benefits 5.
  • Overall, the evidence suggests that steroids, as part of a combination medical therapy, may be helpful in managing symptoms associated with malignant partial bowel obstruction, but further research is needed to fully understand their role in this context 2, 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.